Avoid. RDY scores 36/100 with weak compounder metrics (45 Growth, 38 Value) signaling modest earnings power and limited margin expansion. While leadership alignment is middling (60/100), the real vulnerability lies in a deteriorating competitive position: generic drug pricing pressure and biosimilar competition erode pricing power without offsetting productivity gains. At 24.4× forward P/E, valuation doesn't justify the structural headwinds.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for Dr. Reddy's Laboratories Ltd:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 36/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates Dr. Reddy's Laboratories Ltd (RDY) at 36/100 — an Avoid — fundamentals or risks are too weak. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Avoid. RDY scores 36/100 with weak compounder metrics (45 Growth, 38 Value) signaling modest earnings power and limited margin expansion. While leadership alignment is middling (60/100), the real vulnerability lies in a deteriorating compet
RDY's current Stocky Verdict is 36/100, placing it in the "Avoid" band. This composite combines a 45/100 Compounder score, 60/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for Dr. Reddy's Laboratories Ltd yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
Dr. Reddy's Laboratories Ltd scores 60/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
Dr. Reddy's Laboratories Ltd's Vulnerability Profile scores 0/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to Dr. Reddy's Laboratories Ltd.
Sign up free and unlock the full analysis on RDY — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
Or jump straight to the interactive dashboard for RDY in the app.
